A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS
Status:
Suspended
Trial end date:
2022-04-04
Target enrollment:
Participant gender:
Summary
This is an open-label, phase 1b study to evaluate the safety, tolerability and preliminary
efficacy of IBI188 in combination with Azacitidine in newly diagnosed higher risk MDS
patients.